Shyamala Navada
About
Shyamala Navada is a scholar working on Hematology, Genetics and Molecular Biology.
According to data from OpenAlex, Shyamala Navada has authored 49 papers receiving a total of 574 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Hematology, 16 papers in Genetics and 11 papers in Molecular Biology. Recurrent topics in Shyamala Navada's work include Acute Myeloid Leukemia Research (40 papers), Chronic Myeloid Leukemia Treatments (18 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers). Shyamala Navada is often cited by papers focused on Acute Myeloid Leukemia Research (40 papers), Chronic Myeloid Leukemia Treatments (18 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers). Shyamala Navada collaborates with scholars based in United States, France and Italy. Shyamala Navada's co-authors include Lewis R. Silverman, Michael Lübbert, Gregory P. Kalemkerian, Ann G. Schwartz, P H Lai, John Mascarenhas, Saty Satya‐Murti, Rosalie Odchimar-Reissig, Vesna Najfeld and Amy D. Rodriguez and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Shyamala Navada
43 papers receiving 564 citations
Peers
Shyamala Navada
Guopan Yu China
Daniel Hormaechea‐Agulla Spain
Jamil Dierov United States
Atsushi Muto Japan
Anna Pitto Italy
Jennifer K. Taylor United States
Irene Wong United States
Marit E. Hystad Norway
Jeffrey Sivik United States
Peihong Zhang China
Citations per year, relative to Shyamala Navada Shyamala Navada (= 1×)
peers
Guopan Yu
Countries citing papers authored by Shyamala Navada
Since
Specialization
Citations
This map shows the geographic impact of Shyamala Navada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shyamala Navada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shyamala Navada more than expected).
Fields of papers citing papers by Shyamala Navada
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Shyamala Navada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shyamala Navada. The network helps show where Shyamala Navada may publish in the future.
Co-authorship network of co-authors of Shyamala Navada
This figure shows the co-authorship network connecting the top 25 collaborators of Shyamala Navada. A scholar is included among the top collaborators of Shyamala Navada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shyamala Navada. Shyamala Navada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Komrokji, Rami S., Dylan Supina, Shyamala Navada, et al.. (2025). Transfusion Independence Corresponds With Survival in Patients With Lower-Risk Myelodysplastic Syndrome: Real-World Evidence From United States Insurance Claims. Clinical Lymphoma Myeloma & Leukemia. 25(10). e740–e749.
2.
Mascarenhas, John, Claire Harrison, Prithviraj Bose, et al.. (2024). Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial. Blood. 144(Supplement 1). 1808.1–1808.1.
3.
Stevens, Alexandra M., Maureen M. O’Brien, Charles G. Minard, et al.. (2024). PEPN2312: A Pediatric Early Phase Clinical Trials Network (PEP-CTN) Phase 1 Trial of Imetelstat with Fludarabine/Cytarabine in Pediatric Patients with Relapsed/Refractory AML, MDS, or JMML. Blood. 144(Supplement 1). 4265.4–4265.4.
4.
Komrokji, Rami S., Valeria Santini, Pierre Fenaux, et al.. (2023). Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study. Blood. 142(Supplement 1). 194–194.
5.
Kuykendall, Andrew, Terrence Bradley, Rami S. Komrokji, et al.. (2023). PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF. HemaSphere. 7(S3). e906057e–e906057e.
6.
Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2023). PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF). HemaSphere. 7(S3). e99899f4–e99899f4.
7.
Sekeres, Mikkael A., María Díez‐Campelo, Amer M. Zeidan, et al.. (2023). Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial. Blood. 142(Supplement 1). 6479–6479.
8.
Mascarenhas, John, et al.. (2022). Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk. Blood Research. 57(2). 135–143.
9.
Navada, Shyamala, Guillermo Garcia‐Manero, Rosalie Odchimar-Reissig, et al.. (2020). Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. Leukemia Research. 94. 106369–106369.
10.
Feld, Jonathan, Shyamala Navada, & Lewis R. Silverman. (2020). Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia. Leukemia Research. 97. 106430–106430.
11.
Garcia‐Manero, Guillermo, Shyamala Navada, Pierre Fenaux, et al.. (2019). Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS). Blood. 134(Supplement_1). 4268–4268.
12.
Navada, Shyamala, Guillermo Garcia‐Manero, Ehab Atallah, et al.. (2018). Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients. Blood. 132(Supplement 1). 230–230.
13.
Navada, Shyamala & Lewis R. Silverman. (2016). The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes. Expert Review of Anticancer Therapy. 16(8). 805–810.
14.
Ghosh, Arnab, Nicole A. Carreau, Adeeb Rahman, et al.. (2015). Flow Cytometry Based Detection of MRD in Bone Marrow of Patients with Multiple Myeloma: A Comparison Between Fluorescent-Based Cytometry Versus Cytof. Blood. 126(23). 4195–4195.
15.
Silverman, Lewis R., Amit Verma, Rosalie Odchimar-Reissig, et al.. (2013). A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium. Blood. 122(21). 386–386.
16.
Bhardwaj, Aarti Sonia & Shyamala Navada. (2013). Management of Chemotherapy-Induced Neutropenic Fever. Hospital Practice. 41(1). 96–108.
17.
Dorfman, David, et al.. (2012). A Randomized Trial of Hypnosis for Relief of Pain and Anxiety in Adult Cancer Patients Undergoing Bone Marrow Procedures. Journal of Psychosocial Oncology. 30(3). 281–293.
18.
Navada, Shyamala, Rosalie Odchimar-Reissig, E. P. Reddy, et al.. (2012). Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study. Blood. 120(21). 3794–3794.
19.
Navada, Shyamala & Lewis R. Silverman. (2010). Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions. Current Hematologic Malignancy Reports. 6(1). 5–12.
20.
Silverman, Lewis R., Rosalie Odchimar-Reissig, Shyamala Navada, et al.. (2009). Effects of a Novel Benzyl Styryl Sulfone Derivative ON 01910.Na On the Myelodysplastic Syndrome (MDS) Derived Clone in Patients Relapsing Following Response to Azacitidine (AzaC) Therapy.. Blood. 114(22). 4839–4839.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Guopan Yu Breakdown of academic impact, for papers by Daniel Hormaechea‐Agulla Breakdown of academic impact, for papers by Jamil Dierov Breakdown of academic impact, for papers by Atsushi Muto Breakdown of academic impact, for papers by Anna Pitto Breakdown of academic impact, for papers by Jennifer K. Taylor Breakdown of academic impact, for papers by Irene Wong Breakdown of academic impact, for papers by Marit E. Hystad Breakdown of academic impact, for papers by Jeffrey Sivik Breakdown of academic impact, for papers by Peihong Zhang